BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $26 from $30 and keeps a Buy rating on the shares. While ...

Biopharmaceutical firm Hutchmed China Ltd., backed by billionaire Li Ka-shing, has agreed to sell stakes in a health unit for ...

Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the ...

Hutchmed, a biopharmaceutical company controlled by Hong Kong’s wealthiest person Li Ka-shing, is divesting a 45% stake in a ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds ...

In a move designed to advance its pipeline and its “innovative medicines business,” Chinese biotech Hutchmed will ...

Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including ...

Hutchmed (HCM) announces that it has entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals for $608M in cash to GP Health Service Capital and Shanghai ...

HUTCHMED (China) is not owned by hedge funds. Hutchison Whampoa (China) Limited is currently the largest shareholder, with 39% of shares outstanding. In comparison, the second and third largest ...

HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative ...

Jan 1 (Reuters) - Hutchmed (China)(0013.HK), opens new tab, controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the billionaire and his flagship ...